Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial of ABI-007 (A Cremophor-Free, Protein Stabilized, Nanoparticle Paclitaxel)Administered Weekly in Taxol Resistant Patients With Metastatic Breast Cancer

NCT00046514 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00046514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00046514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial of ABI-007 (A Cremophor-Free, Protein Stabilized, Nanoparticle Paclitaxel)Administered Weekly in Taxol Resistant Patients With Metastatic Breast Cancer
Lead sponsor
Celgene Corporation
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2001
Completion date
Not reported
Enrollment
100
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, metastases, neoplasm